Home World News EMA Recommends Extension of Indications for Sugemalimab World News EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 456 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Partnership in a pandemic: how Credit Suisse delivered an incredible Charity... May 19, 2021 Mom Finding Out Baby’s Gender Uncovers Rare Condition When Doctors See... November 7, 2019 Scientists Focus on Fusion Proteins in Childhood Cancers August 4, 2020 Misdiagnosis: Her Doctor Dismissed Her Concerns For Months Then Told Her... June 2, 2020 Load more HOT NEWS Smoking Initiation Shifting from Teens to Young Adults Updated ROAR Analysis Confirms the Benefit of Dabrafenib Plus Trametinib in... ELCC 2015 News: ‘Real-World’ EGFR Mutation Frequency Results From a Large... Does Sugar Cause Cancer?
